skip to Main Content

RSV immunoprophylaxis impact on RSV Morbidity and Asthma in Healthy Preterm Infants

The goal of this project is to conduct simulation analyses using an existing dataset (from our AHRQ-funded PRIMA study) to assess the possible risks and benefits of immunoprophylaxis among babies 35-36 weeks gestation.

Investigator: Escobar, Gabriel

Funder: National Heart, Lung, and Blood Institute

Explore all studies and publications

Back To Top